Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Richards

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Hepatology (Baltimore, Md.)|September 24, 2022
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 studyMitesh J Borad, Li-Yuan Bai, Donald Richards, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Exon Utilization Improves Risk Stratification for Advanced Heart Failure in Titin CardiomyopathyPeter Deckerman, Jihyeon Lee, Aleksandra Binek, et al.
BMC Cancer|February 17, 2017
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patientsBerta Laquente, Jose Lopez-Martin, Donald Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyNasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancerMinal Barve, James Bender, Neil Senzer, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2025
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trialMilind Javle, Christos Fountzilas, Chih-Yi Liao, et al.
European Urology|May 22, 2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, et al.
Clinical Breast Cancer|June 5, 2019
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 StudyDenise A Yardley, Lowell Hart, Anne Favret, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
Oncology|September 7, 2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid TumorsEmiliano Calvo, Fadi Braiteh, Daniel Von Hoff, et al.
Hepatology (Baltimore, Md.)|September 24, 2022
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 studyMitesh J Borad, Li-Yuan Bai, Donald Richards, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Exon Utilization Improves Risk Stratification for Advanced Heart Failure in Titin CardiomyopathyPeter Deckerman, Jihyeon Lee, Aleksandra Binek, et al.
BMC Cancer|February 17, 2017
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patientsBerta Laquente, Jose Lopez-Martin, Donald Richards, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyNasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancerMinal Barve, James Bender, Neil Senzer, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2025
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trialMilind Javle, Christos Fountzilas, Chih-Yi Liao, et al.
European Urology|May 22, 2024
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, et al.
Clinical Breast Cancer|June 5, 2019
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 StudyDenise A Yardley, Lowell Hart, Anne Favret, et al.
Pageof 4